Bruce Booth
Bruce Booth is an early stage venture capitalist at Atlas Venture who enjoys working with great scientists and entrepreneurs to start new biotech companies. Atlas focuses on seed-stage venture creation around the discovery and development of novel therapeutics. Since joining Atlas in 2005, Bruce has been involved in the founding and funding a number of innovative companies, with a particular focus on capital efficient models for drug R&D.
-
One upside to the drug price pressure debate: more biopharma deals
It seems very likely that the demand for innovative products and pipeline will accelerate in the coming years in order to support the revenue needs of larger commercial-stage companies.
-
What will separate the winners and the losers in the immuno-oncology R&D race?
With the Cancer Moonshot initiative in the spotlight today, here are some insights to consider in the race to develop immuno-oncology drugs.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
CRISPR/Cas9 already is a revolution in molecular biology
Beyond being a revolutionary research tool, CRISPR/Cas9 also holds enormous potential for changing medicine, and this has certainly attracted the attention of the business and investor community in biotech.
-
Pfizer-Allergan ruling sets a dangerous precedent
Fundamentally, my biggest concern with the new rules regards the importance of predictability in business. Strategic planning, essential to running sustainable enterprises, requires the predictability of transparent and forward-looking laws, along with proper due process and accountability.
-
MedCity Influencers, BioPharma
The biotech IPO markets are in turmoil: Here’s a look at the carnage
Of the 142 IPOs since January 2013, 74 percent of them are below their IPO prices.
-
MedCity Influencers, BioPharma
Biotechs today are flush with cash – but low on valuation
The biotech markets have softened. What’s the state of the forthcoming biotech IPO? Atlas Venture’s Bruce Booth weighs in.
-
Why the biotech party may never stop (a JPM Healthcare 2016 primer)
The big question, though, is whether this cycle, in place since the bottom in 2009, is truly unique or special relative to past investment cycles, and how that might affect its sustainability.
-
7 key ingredients in Celgene’s recipe for biopharma dealmaking
Here are the “seven habits”, or more aptly just attributes, of Celgene’s highly successful external R&D strategy.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
